Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

Despite generally high cure rates in patients with metastatic germ cell cancer, patients with progressive disease on first-line cisplatin-based chemotherapy or with relapsed disease following high-dose salvage therapy exhibit a very poor prognosis. Irinotecan has shown antitumour activity in human t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kollmannsberger, C, Rick, O, Klaproth, H, Kubin, T, Sayer, H G, Hentrich, M, Welslau, M, Mayer, F, Kuczyk, M, Spott, C, Kanz, L, Bokemeyer, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364262/
https://www.ncbi.nlm.nih.gov/pubmed/12232755
http://dx.doi.org/10.1038/sj.bjc.66000524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364262/
https://www.ncbi.nlm.nih.gov/pubmed/12232755
http://dx.doi.org/10.1038/sj.bjc.66000524

Ejemplares similares